International Journal of Cardiology
Volume 108, Issue 3 , Pages 326-331 , 14 April 2006

C-reactive protein and atrial fibrillation: “Evidence for the presence of inflammation in the perpetuation of the arrhythmia”

  • Mónica Acevedo

      Affiliations

    • Department of Cardiovascular Diseases, Marcoleta 367, 6th Floor, Catholic University of Chile, Chile
    • Corresponding Author InformationCorresponding authors. Tel.: +56 2 3543334; fax: +56 2 6325275.
    • ,
  • Ramón Corbalán

      Affiliations

    • Department of Cardiovascular Diseases, Marcoleta 367, 6th Floor, Catholic University of Chile, Chile
    • Corresponding Author InformationCorresponding authors. Tel.: +56 2 3543334; fax: +56 2 6325275.
    • ,
  • Sandra Braun

      Affiliations

    • Department of Cardiovascular Diseases, Marcoleta 367, 6th Floor, Catholic University of Chile, Chile
    • ,
  • Jaime Pereira

      Affiliations

    • Department of Thrombosis and Hemostasis, Marcoleta 367, 6th Floor, Catholic University of Chile, Chile
    • ,
  • Carlos Navarrete

      Affiliations

    • Department of Cardiovascular Diseases, Marcoleta 367, 6th Floor, Catholic University of Chile, Chile
    • ,
  • Ilse Gonzalez

      Affiliations

    • Department of Cardiovascular Diseases, Marcoleta 367, 6th Floor, Catholic University of Chile, Chile

Received 12 January 2005 ,Revised 25 April 2005 ,Accepted 14 May 2005.

References 

  1. Benjamin EJMDS, Wolf PAMD, D'Agostino RBP, Silbershatz HP, Kannel WBMD, Levy DMD. Impact of atrial fibrillation on the risk of death: the Framingham heart study. [Article] Circulation. 1998 (September 8);98(10):946–952
  2. Lip GY. Hypercoagulability and haemodynamic abnormalities in atrial fibrillation. [letter; comment.] Heart. 1997 (May);77(5):395–396
  3. Lip GYHMDMab, Lowe GDOMDb, Rumley ABb, Dunn FGMa. Fibrinogen and fibrin d-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. [Article] Am Heart J. 1996 (April);131(4):724–730
  4. Mihm MMD, Yu FMD, Carnes CMD, Reiser PMD, McCarthy PMD, Van Wagoner DMD, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001 (July);104:174–180
  5. Bruins PMD, te Velthuis HMD, Yazdanbakhsh AMD, Jansen PMD, van Hardevelt FMD, de Beaumont EMD, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997 (Nov);96:3542–3548
  6. Frustaci AMD, Chimente CMD, Bellocci FMD, Morgante EMD, Russo MAMD, Maseri AMD. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. [Article] Circulation. 1997 (August 19);96(4):1180–1184
  7. Chung MMD, Martin DMD, Sprecher DMD, Wazni OMD, Kanderian AMD, Carnes CMD, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001 (Dec);104:2886–2891
  8. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. [see comment] Acta Cardiol. 2001 (Dec);56(6):375–380
  9. Kamiyama N. Expression of cell adhesion molecules and the appearance of adherent leukocytes on the left atrial endothelium with atrial fibrillation: rabbit experimental model. Jpn Circ J. 1998 (Nov);62(11):837–843
  10. Roldan VMD, Marin FMD, Blann AMD, Garcia AMD, Marco PMD, Sogorb FMD, et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J. 2003 (Jul);24(14):1373–1380
  11. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999 (Dec);45(12):2136–2141
  12. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454
  13. Ross R. Mechanisms of disease: atherosclerosis—an inflammatory disease. [Article] N Engl J Med. 1999 (January 14);340(2):115–126
  14. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. [Review, 95 refs] Circulation. 2002 (Mar 5);105(9):1135–1143
  15. Ridker P, Cushman M, Stampfer M, Tracy R, CH H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  16. Ridker PM. High-sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813–1818
  17. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  18. Morrow DMD, Rifai NMD, Antman EMD, Weiner DMD, McCabe CMD, Cannon CMD, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1998;31:1460–1465
  19. Lagrand WMD, Visser CMD, Hermens WMD, Niessen HMD, Verheugt FMD, Wolbink GMD, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation. 1999 (Jul);100:96–102
  20. Torzewski MMD, Rist CMD, Mortensen RMD, Zwaka TMD, Bienek MMD, Waltenberger JMD, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000 (Sep);20(9):2094–2099
  21. Venugopal SKP, Devaraj SP, Yuhanna IMS, Shaul PMD, Jialal IMDP. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. [Miscellaneous Article] Circulation. 2002 (September 17);106(12):1439–1441
  22. Aviles RMD, Martin DMD, Apperson-Hansen CMD, Houghtaling PMD, Rautaharju PMD, Kronmal RMD, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003 (Dec);108:3006–3010
  23. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J. 2004;25:1100–1107
  24. Stroke Prevention in Atrial Investigators . Predictors of thromboembolism in atrial fibrillation: clinical features of patients at risk. Ann Intern Med. 1992 (Jan 1);116(1):1–5
  25. Carnes CMD, Chung MMD, Nakayama TMD, Nakayama HMD, Baliga RMD, Piao SMD, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res. 2001 (Sep 14);89(6):E32–E38
  26. Di Napoli MMD, Papa FMD for the Villa Pini Stroke Data Bank I. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. [Article] Stroke. 2002 (July);33(7):1763–1771
  27. Conway DSG, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol. 2004;43:2075–2082

PII: S0167-5273(05)00740-0

doi: 10.1016/j.ijcard.2005.05.017

International Journal of Cardiology
Volume 108, Issue 3 , Pages 326-331 , 14 April 2006

Article Tools

* Image Usage & Resolution